Mercator Therapeutics and Pepscan Therapeutics Establish Research and Licensing Collaboration
Mercator’s Homing Peptides are discovered through a unique in vivo screening process, including screening in consenting end-stage cancer patients. These peptides have been demonstrated in vivo to bind to receptors that are highly expressed on human tumors and induce internalization of both the peptide and the receptor. Pepscan’s CLIPS technology will be applied to improve the potency and stability of peptides by locking the peptides into the biologically active conformation.
Under the terms of the Research and License Agreement between Mercator and Pepscan, Pepscan will increase the potency and stability of Mercator’s Homing Peptides and license to Mercator the associated intellectual property rights. Mercator will pay Pepscan undisclosed research funding, milestones, and royalties in connection with the development of optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumor-killing payloads.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.